The Supreme Court heard arguments April 28 in Monsanto v. Durnell, weighing whether FIFRA preempts Roundup failure-to-warn claims affecting 65,000 pending cases.
The Supreme Court heard oral argument on April 28 in *Monsanto Co. v. Durnell*, a case that will determine whether the Federal Insecticide, Fungicide, and Rodenticide Act preempts state-law failure-to-warn claims tied to Roundup's alleged link to non-Hodgkin's lymphoma [1]. The case arrives as roughly 65,000 similar claims remain pending across state and federal courts, making the Court's eventual ruling one of the most consequential product-liability decisions in years [2]. Bayer AG, which acquired Monsanto in 2018, has faced sustained litigation over glyphosate, the active ingredient in Roundup, and has already offered a $7.25 billion settlement to resolve a portion of the docket [2].
The argument presented the Court with a direct conflict between federal regulatory approval and state tort liability. Bayer's position is that FIFRA's labeling scheme, administered by the Environmental Protection Agency, occupies the field and forecloses any state requirement imposing labeling obligations beyond what EPA has approved [1]. Plaintiffs counter that state failure-to-warn claims impose no additional requirement but instead enforce a duty the company itself failed to meet independent of federal standards [2]. The Solicitor General filed an amicus brief siding with Bayer's preemption argument, lending the federal government's weight to the defense posture [1].
The stakes extend well beyond the immediate parties. A ruling for Bayer would effectively extinguish tens of thousands of pending state-court cases that rely on the same failure-to-warn theory [2]. A ruling for plaintiffs would preserve state-court access and leave Bayer facing litigation exposure that analysts have estimated at more than $11 billion [2]. The decision will also set a preemption benchmark for all pesticide manufacturers operating under FIFRA, reshaping how the industry manages tort risk going forward [1].
The Court is expected to issue a decision before its term concludes in late June 2026 [1]. In the interim, Bayer's settlement negotiations remain active, though the outcome of the oral argument may recalibrate plaintiff leverage and affect the trajectory of any global resolution [2]. Plaintiffs' counsel and litigation financiers will be watching the opinion closely for signals on how broadly or narrowly the Court defines the preemption field under FIFRA.